Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases
© 2017 The British Pharmacological Society..
The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.
LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:175 |
|---|---|
| Enthalten in: |
British journal of pharmacology - 175(2018), 2 vom: 18. Jan., Seite 192-222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berger, Nathan A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 20.08.2018 Date Revised 09.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bph.13748 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM26908410X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM26908410X | ||
| 003 | DE-627 | ||
| 005 | 20231224223859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bph.13748 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0896.xml |
| 035 | |a (DE-627)NLM26908410X | ||
| 035 | |a (NLM)28213892 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berger, Nathan A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.08.2018 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 The British Pharmacological Society. | ||
| 520 | |a The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors | ||
| 520 | |a LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Besson, Valerie C |e verfasserin |4 aut | |
| 700 | 1 | |a Boulares, A Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Bürkle, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarugi, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Robert S |e verfasserin |4 aut | |
| 700 | 1 | |a Curtin, Nicola J |e verfasserin |4 aut | |
| 700 | 1 | |a Cuzzocrea, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Ted M |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Valina L |e verfasserin |4 aut | |
| 700 | 1 | |a Haskó, György |e verfasserin |4 aut | |
| 700 | 1 | |a Liaudet, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Moroni, Flavio |e verfasserin |4 aut | |
| 700 | 1 | |a Pacher, Pál |e verfasserin |4 aut | |
| 700 | 1 | |a Radermacher, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Salzman, Andrew L |e verfasserin |4 aut | |
| 700 | 1 | |a Snyder, Solomon H |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, Francisco Garcia |e verfasserin |4 aut | |
| 700 | 1 | |a Strosznajder, Robert P |e verfasserin |4 aut | |
| 700 | 1 | |a Sümegi, Balázs |e verfasserin |4 aut | |
| 700 | 1 | |a Swanson, Raymond A |e verfasserin |4 aut | |
| 700 | 1 | |a Szabo, Csaba |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of pharmacology |d 1968 |g 175(2018), 2 vom: 18. Jan., Seite 192-222 |w (DE-627)NLM000001325 |x 1476-5381 |7 nnns |
| 773 | 1 | 8 | |g volume:175 |g year:2018 |g number:2 |g day:18 |g month:01 |g pages:192-222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bph.13748 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 175 |j 2018 |e 2 |b 18 |c 01 |h 192-222 | ||